KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Inventory (2016 - 2025)

Historic Inventory for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $443.9 million.

  • West Pharmaceutical Services' Inventory rose 1774.54% to $443.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $443.9 million, marking a year-over-year increase of 1774.54%. This contributed to the annual value of $443.9 million for FY2025, which is 1774.54% up from last year.
  • According to the latest figures from Q4 2025, West Pharmaceutical Services' Inventory is $443.9 million, which was up 1774.54% from $438.0 million recorded in Q3 2025.
  • In the past 5 years, West Pharmaceutical Services' Inventory ranged from a high of $449.4 million in Q2 2023 and a low of $310.2 million during Q1 2021
  • Its 5-year average for Inventory is $406.3 million, with a median of $415.6 million in 2022.
  • In the last 5 years, West Pharmaceutical Services' Inventory skyrocketed by 3426.82% in 2022 and then plummeted by 1327.35% in 2024.
  • West Pharmaceutical Services' Inventory (Quarter) stood at $378.4 million in 2021, then rose by 9.62% to $414.8 million in 2022, then increased by 4.8% to $434.7 million in 2023, then dropped by 13.27% to $377.0 million in 2024, then grew by 17.75% to $443.9 million in 2025.
  • Its last three reported values are $443.9 million in Q4 2025, $438.0 million for Q3 2025, and $421.1 million during Q2 2025.